自2006年成立以来，禾元生物以水稻胚乳细胞生物反应器技术为核心，构建了高效重组蛋白表达平台和 重组蛋白纯化技术平台，用近20年时间攻坚实现了"稻米造血"的创新技术。核心产品重组人白蛋白注射 液（水稻）于今年7月获批上市，改写了该类产品依赖血浆提取的历史。截至目前，公司已取得80余项 发明专利，建成年产10吨原液及100万支制剂的智能化生产线，并已与国药控股、贝达药业等多家药品 经销商签订经销协议，完成了全国30余个省市区域的销售网络布局。公司在技术和商业化上均实现了从 0到1的突破。同时，公司已于2024年9月开工新建年产120吨原液的产业化基地项目，将助力公司实现规 模化生产，抢占重组人白蛋白市场先发优势，强化公司的核心竞争力。 此外，作为科创板第五套标准重启后首家过会企业、科创成长层首批上市企业，禾元生物的此次发行上 市彰显了资本市场支持科技创新，增强对优质科技型企业包容性适应性的政策导向。未来将会吸引更多 长期资本进入科技创新领域，促进资本与科技创新深度融合，从而更好地发挥资本市场对科技创新的推 动作用。 尊敬的各位嘉宾、各位投资者： 大家好！ 今天，我们非常荣幸地通过网络平台，与关注禾元生物的广大投 ...

根据目前的发行安排，下周有5只新股申购，包括2只主板新股、3只科创板新股。 从日程安排看，下周每个交易日都有一只新股申购。值得一提的是，周一的深市主板新股马可波罗、周四的科创板新股西安奕材，新股发行数量都 比较多，中签率可能较高。 | | | 下周新股申购安排 | | | | --- | --- | --- | --- | --- | | 日期 | 新股 | 发行价/股 | 发行市盈率 | 上市板 | | 周一 (10月13日) | 马可波罗 (申购代码:001386) | 13.75元 | 14.27 | 深市主板 | | 周二 (10月14日) | 不元生物 (申购代码: 787765) | 待定 | | 科创板 | | 周三 (10月15日) | 超颖电子 (申购代码:732175) | 待定 | | 沪市主板 | | 周四 (10月16日) | 西安奕材 (申购代码: 787783) | 待定 | | 科创板 | | 周五 (10月17日) | 必贝特 (申购代码: 787759) | 待定 | | 科创板 | 马可波罗是国内建筑陶瓷行业龙头。 马可波罗的发行价为13.75元/股，发行市盈率为14.2 ...

Core Viewpoint - Bidafarma, a well-known innovative pharmaceutical company, is planning to list on the Hong Kong Stock Exchange to enhance its capital strength and international competitiveness [2]. Company Overview - As of September 29, Bidafarma's A-share market capitalization is 27.68 billion yuan [2]. - The company focuses on developing innovative targeted therapies for various cancers, including lung, breast, kidney, colorectal, and pancreatic cancers, as well as blood diseases and ophthalmology [2]. Fundraising Purpose - The funds raised from the IPO will be allocated to four main areas: 1. Financing for the research and development of innovative drug candidates 2. Funding for potential acquisitions to expand the pipeline and develop Bidafarma's innovative ecosystem 3. Strengthening the marketing network and market expansion in key therapeutic areas 4. Working capital and other general corporate purposes [2]. Product Pipeline - Bidafarma has successfully launched eight innovative targeted cancer therapies and biosimilars, with over ten innovative drug development projects at various stages [2]. - The eight core products include: 1. Hydrochloride Ercitinib Tablets 2. Hydrochloride Ensatinib Capsules 3. Bevacizumab Injection 4. Mesylate Bafetinib Capsules 5. Voronib Tablets 6. Tarceva Capsules 7. Trastuzumab Injection 8. Recombinant Human Albumin Injection (Rice) - Among these, Hydrochloride Ercitinib Tablets, Hydrochloride Ensatinib Capsules, Voronib Tablets, and Tarceva Capsules are self-developed products, while the other four are collaborative products [2]. Financial Performance - In the first half of 2025, Bidafarma reported a revenue of 1.731 billion yuan, representing a year-on-year increase of 15.37%. However, the net profit attributable to shareholders decreased by 37.53% to 140 million yuan [3]. - The company emphasizes a proven and repeatable success model that integrates commercialization, research and development, strategic partnerships, and an innovative ecosystem, which collectively drive its transformation from a domestic pioneer to a globally competitive platform pharmaceutical company [3].

Core Insights - China's bio-economy is showing a positive trend, with significant advancements in CAR-T cell therapy, original drug production, and brain-machine interface medical devices, positioning the country as the second-largest biopharmaceutical market globally [1][2] Industry Overview - The global bio-manufacturing industry is receiving heightened attention from major economies, with increased funding for genetic and cell engineering research, biomass utilization, and bio-based product development [2] - The number of CAR-T clinical research centers worldwide has grown to 2069 in 2024, a 60% increase from 1297 in 2020, with China hosting 388 centers, ranking second globally [2] - China has achieved a record high in the proportion of self-developed new drugs, with 93 new drugs approved by the National Medical Products Administration in 2024, marking a five-year peak [2] Research and Development - In 2024, China published over 20,000 SCI papers in the medical equipment field, leading globally in research output [3] - The bio-economy in China is characterized by a robust industrial foundation, with significant growth in the pharmaceutical and chemical sectors driven by advancements in synthetic biology and high-throughput screening technologies [3] Industry Transformation - The bio-industry is transitioning from "quantitative accumulation" to "qualitative leap," focusing on core technology breakthroughs, product quality upgrades, and enhancing supply chain resilience [4] - Notable innovations include the approval of the world's first "rice-derived" human serum albumin injection and the launch of the world's first 5.0T whole-body MRI system [4] Future Prospects - Innovations in synthetic biology and gene editing are driving rapid growth in bio-manufacturing, outpacing GDP growth, and positioning the bio-economy as a crucial sector in the future global economy [5]

Core Viewpoint - The issuance of new registered companies in the Sci-Tech Innovation Growth Layer is ready, with Wuhan Heyuan Biotechnology Co., Ltd. initiating its issuance, marking a significant step in the "1+6" reform of the Sci-Tech Innovation Board [1][3]. Group 1: Company Overview - Heyuan Biotechnology is the first company to start the issuance process after the resumption of the fifth set of standards for the Sci-Tech Innovation Board [4]. - The company has developed a globally pioneering "rice-derived blood" technology, supported by the national "Major New Drug Creation" program [4]. - Heyuan's self-developed innovative drug, recombinant human albumin injection (from rice), was approved for market launch in July, aiming to reduce China's long-term reliance on imported human serum albumin [4]. Group 2: Market Context - The issuance of Heyuan Biotechnology reflects the implementation of the "1+6" reform, enhancing the system's inclusiveness and adaptability for high-quality technology enterprises [4]. - The company is the first to adopt differentiated lock-up and allocation arrangements for offline issuance, with a minimum lock-up ratio of 40% for offline investors [4]. - The Shanghai Stock Exchange has revised its issuance and underwriting rules, allowing unprofitable companies to use agreed lock-up methods, encouraging professional institutions to play a larger role in new stock pricing [5]. Group 3: Industry Developments - Since the announcement of the "1+6" reform policy in June, 15 companies have applied for IPOs on the Sci-Tech Innovation Board, including four unprofitable companies [6]. - Three unprofitable companies have already received IPO registration approval, with two of them under the fifth set of standards [7]. - The Shanghai Stock Exchange has completed system tests for the new registered companies in the Sci-Tech Innovation Growth Layer, with 5 million investors having opened trading permissions for this layer [7].

9月22日晚间，武汉禾元生物科技股份有限公司（以下简称禾元生物）在上交所网站披露招股意向书、发行安排及初步询价公告，正式启动发行工作。 | 证券代码 | 证券简称 | 公告标题 | 公告时间 | | --- | --- | --- | --- | | 600255 | 鑫科材料 | 鑫科材料关于非公开发行科技创新公司债券获得上海证券交易所挂牌转让无异议函的公告 | 2025-09-23 | | 603598 | 引力传媒 | 引力传媒:关于2024年限制性股票与股票期权激励计划第一个解除限售期限制性股票解锁暨上市公告 | 2025-09-23 | | 603616 | 韩建河山 | 关于2023年限制性股票激励计划第二个解除限售期解除限售暨上市的公告 | 2025-09-23 | | 603773 | 沃格光电 | 江西沃格光电集团股份有限公司关于非公开发行限售股上市流通的公告 | 2025-09-23 | | 688193 | 仁度生物 | 关于公司首次公开发行部分限售股上市流通的公告 | 2025-09-23 | | 688295 | 中复神鹰 | 中复神鹰碳纤维股份有限公司首次公开发行部分限售股上市流通 ...

科创成长层将迎来首家新注册企业发行，科创板"1+6"改革又迈出重要一步。 9月22日晚，武汉禾元生物科技股份有限公司（以下简称"禾元生物"）在上交所网站披露招股意向书、 发行安排及初步询价公告，正式启动发行工作。 由此，禾元生物成为既是重启科创板第五套标准后首家过会并取得注册批文的企业，也是科创成长层新 注册企业中首家启动发行的企业。同时，禾元生物也是首家采用网下发行差异化限售与配售安排的公 司。 市场人士指出，鼓励更多"看得准、拿得住"的专业机构在新股发行定价中发挥更大作用，可以促进新股 合理定价。 据上交所介绍，目前已有500万户投资者开通科创成长层交易权限，上交所技术系统完成全网通关测 试、近日已陆续上线，科创成长层新注册企业发行准备就绪。 禾元生物试水多项新制度 上交所表示，禾元生物启动发行，是落实科创板"1+6"改革、增强对优质科技型企业的制度包容性和适 应性的重要体现，充分彰显了尊重科技创新规律、支持优质科技企业发展、更好服务新质生产力的政策 导向。 作为一家创新型生物医药企业，禾元生物全球首创的"稻米造血"技术获得了国家"重大新药创制"科技重 大专项的支持，自主研发的创新药重组人白蛋白注射液（水 ...

Group 1 - He Yuan Bio is officially launching its issuance process, becoming the first company to initiate this step in the new registration of the Sci-Tech Innovation Board's growth tier [1][4][6] - The company has developed a globally innovative "rice-derived blood" technology, which has received support from the national "Major New Drug Creation" program [7] - He Yuan Bio's recombinant human albumin injection (from rice) has been approved for market release, addressing China's long-standing reliance on imported human serum albumin [7] Group 2 - The issuance of new registered enterprises in the Sci-Tech Innovation Board's growth tier is progressing steadily, with the technical systems of the Shanghai Stock Exchange having completed testing [11][12] - Since the announcement of the "1+6" reform policy in June, 15 companies have applied for IPOs, including four unprofitable enterprises [9] - The Shanghai Stock Exchange has implemented various measures to enhance market attractiveness and inclusivity, supporting the development of technological innovation and new productive forces [14]

Core Viewpoint - He Yuan Bio is set to become a new member of the Sci-Tech Innovation Board as it officially starts its issuance process, marking a significant step in the "1+6" reform of the Sci-Tech Board [2][4]. Group 1: Company Overview - Wuhan He Yuan Bio Technology Co., Ltd. is the first company to initiate the issuance process after the re-launch of the fifth set of standards for the Sci-Tech Board [6]. - He Yuan Bio has developed a globally pioneering "rice-derived hematopoietic" technology, which has received support from the national "Major New Drug Creation" program [6]. - The company's innovative drug, recombinant human albumin injection (from rice), was approved for market release by the National Medical Products Administration in July, aiming to reduce China's reliance on imported human serum albumin [6]. Group 2: Market Context - The issuance of He Yuan Bio is a reflection of the policy direction to enhance the adaptability and inclusiveness of the Sci-Tech Board for high-quality technology enterprises [6]. - Since the announcement of the "1+6" reform policy in June, the Sci-Tech Board has received 15 new IPO applications, including four from unprofitable companies [9]. - The Shanghai Stock Exchange has completed the technical system testing for the new registration of the Sci-Tech Growth Layer, with 5 million investors already authorized to trade in this layer [10]. Group 3: Issuance Details - He Yuan Bio is the first company to adopt differentiated lock-up and allocation arrangements for offline issuance, with a minimum lock-up ratio of 40% for offline investors [6]. - The company has set three tiers of differentiated lock-up levels for investor bids, with the highest lock-up tier having a distribution ratio at least nine times that of the lowest tier [6][7]. - The recent revision of the issuance and underwriting rules by the Shanghai Stock Exchange allows unprofitable companies to adopt agreed lock-up methods, encouraging professional institutions to play a larger role in new stock pricing [7].

禾元生物启动发行，是落实科创板"1+6"改革、增强对优质科技型企业的制度包容性和适应性的重要体 现，充分彰显了尊重科技创新规律、支持优质科技企业发展、更好服务新质生产力的政策导向。作为一 家创新型生物医药企业，禾元生物全球首创的"稻米造血"技术获得了国家"重大新药创制"科技重大专项 的支持，自主研发的创新药重组人白蛋白注射液（水稻）已于今年7月通过国家药监局审评获批上市， 有望解决我国人血清白蛋白长期依赖进口的局面。 值得一提的是，根据"科创板八条"的相关试点安排，禾元生物也是首家采用网下发行差异化限售与配售 安排的公司。根据禾元生物披露的公告文件，其网下整体限售比例不低于40%，对投资者报价设置了3 档差异化限售档位，申购最高限售档位投资者的配售比例不低于最低限售档位的9倍。 今年以来，在中国证监会领导下，上交所多措并举不断推进"科创板八条"和科创板"1+6"改革政策落 地，各项配套制度规则已全部发布实施，存量32家未盈利企业已于规则发布当日纳入科创成长层。上交 所表示，目前科创成长层首批新注册企业发行上市的各项工作正在有序稳步推进中，证券公司已有序组 织投资者签署参与科创成长层交易的风险揭示书，目前已有5 ...